Eliem Therapeutics Cost of Goods Sold 2021-2024 | CLYM

Eliem Therapeutics cost of goods sold from 2021 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
Eliem Therapeutics Annual Cost of Goods Sold
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
Eliem Therapeutics Quarterly Cost of Goods Sold
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.342B $0.000B
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
Stock Name Country Market Cap PE Ratio
Chesapeake Energy (EXE) United States $11.186B 28.69
Hammerson (HMSND) United Kingdom $2.121B 0.00
American Software (LGTY) United States $0.388B 29.97
Learn CW Investment (INV) United States $0.204B 0.00
Nicholas Financial (OMCC) United States $0.079B 0.00
ExcelFin Acquisition (BDMD) $0.033B 0.00
Caravelle Group (HTCO) Singapore $0.024B 0.00
Recruiter (NIXX) United States $0.007B 0.00